Literature DB >> 34903667

Components of the phosphatidylserine endoplasmic reticulum to plasma membrane transport mechanism as targets for KRAS inhibition in pancreatic cancer.

Walaa E Kattan1,2, Junchen Liu1, Dina Montufar-Solis1, Hong Liang1, Bhargavi Brahmendra Barathi2, Ransome van der Hoeven3, Yong Zhou1,2, John F Hancock4,2.   

Abstract

KRAS is mutated in 90% of human pancreatic ductal adenocarcinomas (PDACs). To function, KRAS must localize to the plasma membrane (PM) via a C-terminal membrane anchor that specifically engages phosphatidylserine (PtdSer). This anchor-binding specificity renders KRAS-PM localization and signaling capacity critically dependent on PM PtdSer content. We now show that the PtdSer lipid transport proteins, ORP5 and ORP8, which are essential for maintaining PM PtdSer levels and hence KRAS PM localization, are required for KRAS oncogenesis. Knockdown of either protein, separately or simultaneously, abrogated growth of KRAS-mutant but not KRAS-wild-type pancreatic cancer cell xenografts. ORP5 or ORP8 knockout also abrogated tumor growth in an immune-competent orthotopic pancreatic cancer mouse model. Analysis of human datasets revealed that all components of this PtdSer transport mechanism, including the PM-localized EFR3A-PI4KIIIα complex that generates phosphatidylinositol-4-phosphate (PI4P), and endoplasmic reticulum (ER)-localized SAC1 phosphatase that hydrolyzes counter transported PI4P, are significantly up-regulated in pancreatic tumors compared to normal tissue. Taken together, these results support targeting PI4KIIIα in KRAS-mutant cancers to deplete the PM-to-ER PI4P gradient, reducing PM PtdSer content. We therefore repurposed the US Food and Drug Administration-approved hepatitis C antiviral agent, simeprevir, as a PI4KIIIα inhibitor In a PDAC setting. Simeprevir potently mislocalized KRAS from the PM, reduced the clonogenic potential of pancreatic cancer cell lines in vitro, and abrogated the growth of KRAS-dependent tumors in vivo with enhanced efficacy when combined with MAPK and PI3K inhibitors. We conclude that the cellular ER-to-PM PtdSer transport mechanism is essential for KRAS PM localization and oncogenesis and is accessible to therapeutic intervention.

Entities:  

Keywords:  KRAS; ORP5; ORP8; PI4KA; phosphatidylserine

Mesh:

Substances:

Year:  2021        PMID: 34903667      PMCID: PMC8713765          DOI: 10.1073/pnas.2114126118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  55 in total

1.  H-ras, K-ras, and inner plasma membrane raft proteins operate in nanoclusters with differential dependence on the actin cytoskeleton.

Authors:  Sarah J Plowman; Cornelia Muncke; Robert G Parton; John F Hancock
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-13       Impact factor: 11.205

2.  Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- but not β-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation.

Authors:  Michael J Waring; David M Andrews; Paul F Faulder; Vikki Flemington; Jennifer C McKelvie; Sarita Maman; Marian Preston; Piotr Raubo; Graeme R Robb; Karen Roberts; Rachel Rowlinson; James M Smith; Martin E Swarbrick; Iris Treinies; Jon J G Winter; Robert J Wood
Journal:  Chem Commun (Camb)       Date:  2013-12-24       Impact factor: 6.222

3.  Drug combination studies and their synergy quantification using the Chou-Talalay method.

Authors:  Ting-Chao Chou
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

4.  Pharmacological and genetic targeting of the PI4KA enzyme reveals its important role in maintaining plasma membrane phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate levels.

Authors:  Naveen Bojjireddy; Janos Botyanszki; Gerald Hammond; Donald Creech; Richard Peterson; Daniel C Kemp; Mark Snead; Randy Brown; Alastair Morrison; Steve Wilson; Steve Harrison; Chris Moore; Tamas Balla
Journal:  J Biol Chem       Date:  2014-01-10       Impact factor: 5.157

5.  The role of oxysterol binding protein-related protein 5 in pancreatic cancer.

Authors:  Shinji Ishikawa; Youhei Nagai; Toshirou Masuda; Yoshikatsu Koga; Tadahiko Nakamura; Yu Imamura; Hiroshi Takamori; Masahiko Hirota; Akihiro Funakosi; Masakazu Fukushima; Hideo Baba
Journal:  Cancer Sci       Date:  2009-12-16       Impact factor: 6.716

6.  Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US.

Authors:  Wei Wang; Vincent Lo Re; Yi Guo; Hong Xiao; Joshua Brown; Haesuk Park
Journal:  Aliment Pharmacol Ther       Date:  2020-09-15       Impact factor: 8.171

7.  Signal integration by lipid-mediated spatial cross talk between Ras nanoclusters.

Authors:  Yong Zhou; Hong Liang; Travis Rodkey; Nicholas Ariotti; Robert G Parton; John F Hancock
Journal:  Mol Cell Biol       Date:  2013-12-23       Impact factor: 4.272

8.  Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells.

Authors:  Yu Zhang; Michelle Zoltan; Erick Riquelme; Hanwen Xu; Ismet Sahin; Susana Castro-Pando; Maria Fernanda Montiel; Kyle Chang; Zhengyu Jiang; Jianhua Ling; Sonal Gupta; William Horne; Melissa Pruski; Huamin Wang; Shao-Cong Sun; Guillermina Lozano; Paul Chiao; Anirban Maitra; Steven D Leach; Jay K Kolls; Eduardo Vilar; Timothy C Wang; Jennifer M Bailey; Florencia McAllister
Journal:  Gastroenterology       Date:  2018-03-29       Impact factor: 22.682

9.  Lenz-Majewski mutations in PTDSS1 affect phosphatidylinositol 4-phosphate metabolism at ER-PM and ER-Golgi junctions.

Authors:  Mira Sohn; Pavlina Ivanova; H Alex Brown; Daniel J Toth; Peter Varnai; Yeun Ju Kim; Tamas Balla
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-04       Impact factor: 11.205

10.  Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.

Authors:  Hema Adhikari; Walaa E Kattan; Shivesh Kumar; Pei Zhou; John F Hancock; Christopher M Counter
Journal:  Nat Commun       Date:  2021-09-09       Impact factor: 17.694

View more
  1 in total

1.  Therapeutic and prognostic potential of GPCRs in prostate cancer from multi-omics landscape.

Authors:  Shiqi Li; Jianfang Chen; Xin Chen; Jin Yu; Yanzhi Guo; Menglong Li; Xuemei Pu
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.